What is Solarea Bio?
Founded in 2017, Solarea Bio operates at the intersection of food science and human health. The company specializes in identifying and developing microbiome-based interventions derived from untapped microbial sources found in healthy food systems. By focusing on the gut-musculoskeletal axis and inflammatory processes, Solarea Bio is positioning itself as a leader in the next generation of preventative and therapeutic health solutions. Its market position is defined by a unique synthesis of nutritional science and biotechnology, aiming to disrupt traditional approaches to chronic disease management through proprietary, evidence-based microbial applications.
How much funding has Solarea Bio raised?
Solarea Bio has raised a total of $26.2M across 2 funding rounds:
Series A
$11.2M
Series B
$15M
Series A (2020): $11.2M with participation from Viking Global Investors, S2G Ventures, Gisev Family Office, and BOLD Capital Partners
Series B (2023): $15M led by Viking Global Investors, S2G Ventures, and BOLD Capital Partners
Key Investors in Solarea Bio
Viking Global Investors
A global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across industries and geographies.
S2G Ventures
A multi-stage food and agriculture venture fund investing in entrepreneurs whose products and services meet the shifting demands for healthy and sustainable food across the entire supply chain.
BOLD Capital Partners
A venture capital firm dedicated to investing in entrepreneurs and technologies that aim to transform the world by identifying emerging science that can disrupt and democratize large markets.
What's next for Solarea Bio?
With the recent infusion of capital, Solarea Bio is well-positioned to accelerate its clinical development pipeline and scale its research operations. The company is expected to prioritize the validation of its lead candidates, moving from foundational discovery toward more advanced human trials. As the firm matures, the focus will likely shift toward strategic partnerships within the pharmaceutical and nutritional sectors to commercialize its microbiome-based assets. This enterprise-level financing provides the necessary runway to refine its proprietary platform, ensuring that Solarea Bio remains at the forefront of the biotech sector as it seeks to redefine the standard of care for inflammatory conditions.
See full Solarea Bio company page
